IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) Stock Price, Forecast & Analysis
Europe - BIT:1IOVA - US4622601007 - Common Stock
1IOVA.MI Key Statistics, Chart & Performance
The current stock price of 1IOVA.MI is 2.2675 EUR.
1IOVA.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 73.08 | 48.01B | ||
| 1AE.DE | ARGENX SE | 72.09 | 47.36B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.63B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.33B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.33B | ||
| GLPG.AS | GALAPAGOS NV | 24.38 | 1.80B | ||
| 5CV.DE | CUREVAC NV | 5.24 | 1.03B | ||
| NANO.PA | NANOBIOTIX | N/A | 876.56M | ||
| PHIL.MI | PHILOGEN SPA | 20.53 | 684.22M | ||
| IVA.PA | INVENTIVA SA | N/A | 494.46M | ||
| FYB.DE | FORMYCON AG | N/A | 366.65M | ||
| ALCLS.PA | CELLECTIS | N/A | 341.61M |
Related stock screener links
About 1IOVA.MI
Company Profile
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 838 full-time employees. The company went IPO on 2008-06-20. The company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The company is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. The company also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.
Company Info
IOVANCE BIOTHERAPEUTICS INC
825 Industrial Road, 4th Floor
San Carlos CALIFORNIA US
Employees: 838
Phone: 16502607120
IOVANCE BIOTHERAPEUTICS INC / 1IOVA.MI FAQ
Can you describe the business of IOVANCE BIOTHERAPEUTICS INC?
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 838 full-time employees. The company went IPO on 2008-06-20. The company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The company is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. The company also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.
Can you provide the latest stock price for IOVANCE BIOTHERAPEUTICS INC?
The current stock price of 1IOVA.MI is 2.2675 EUR. The price increased by 12.95% in the last trading session.
Does 1IOVA stock pay dividends?
1IOVA.MI does not pay a dividend.
How is the ChartMill rating for IOVANCE BIOTHERAPEUTICS INC?
1IOVA.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists 1IOVA stock?
1IOVA.MI stock is listed on the Euronext Milan exchange.
Can you provide the growth outlook for IOVANCE BIOTHERAPEUTICS INC?
The Revenue of IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) is expected to grow by 63.25% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
1IOVA.MI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to 1IOVA.MI.
1IOVA.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1IOVA.MI. While 1IOVA.MI seems to be doing ok healthwise, there are quite some concerns on its profitability.
1IOVA.MI Financial Highlights
Over the last trailing twelve months 1IOVA.MI reported a non-GAAP Earnings per Share(EPS) of -1.02. The EPS increased by 20.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.94% | ||
| ROE | -56.62% | ||
| Debt/Equity | 0 |
1IOVA.MI Forecast & Estimates
18 analysts have analysed 1IOVA.MI and the average price target is 7.25 EUR. This implies a price increase of 219.65% is expected in the next year compared to the current price of 2.2675.
For the next year, analysts expect an EPS growth of 10.2% and a revenue growth 63.25% for 1IOVA.MI